Korsana Biosciences, Inc. (KRSA) - Guggenheim 3rd Annual Healthcare Innovation Conference - KORSANA BIOSCIENCES INC

Explicit Guidance:

• No financial guidance provided (revenue, earnings, margins, capex, cash flow).
• No specific milestones or timeline estimates provided beyond general regulatory filing windows (e.g., "end of this year," "early next year").

Business-Segment Outlook:

• Lead Program (KRSA-028): Aiming to launch as a monthly subcutaneous autoinjector for home use with high tolerability and rapid plaque clearance, potentially becoming a best-in-class asset in the amyloid-targeting segment.
• Platform Utilization: While currently laser-focused solely on KRSA-028 and amyloid clearance, management acknowledges the shuttle platform's potential for expansion into Tau and other neurodegenerative targets; no new programs expected within the next year or so.
• Clinical Development Timeline:
  • CTA Filing: Expected to be filed for the Single Ascending Dose (SAD) study in Australia/New Zealand by the end of the current year.
  • IND Submission: Planned for early next year to facilitate Multiple Ascending Dose (MAD) studies, with primary patient enrollment anticipated in the U.S.
  • Data Readouts: SAD/PK/brain penetration data expected in the middle of next year; interim proof-of-concept (plaque clearance) data from MAD cohorts expected shortly thereafter.
• Regulatory Strategy: Designed as an integrated Phase 1/2 study intended to be "Phase 3 enabling," aiming to generate sufficient safety data (similar to Roche's Trontinemab expansion cohorts of ~75 patients) to secure global regulatory buy-in for a direct pivot to Phase 3.

Market and Competitive Outlook:

• Market Size: Anticipates the Alzheimer's disease (AD) market will become "gargantuan," potentially 6–7 times the size of the Multiple Sclerosis (MS) market, with room for "multiple winners."
• Differentiation Strategy: Positioning KRSA-028 to improve upon Roche's Leqembi (Trontinemab) and Lili's products (Aduhelm/Donanemab) by offering superior convenience (subcutaneous vs. IV), lower dosing frequency (monthly), and a better safety profile (reduced ARIA risk, no reticulocyte depletion).
• Competitive Landscape: Expects a sequential wave of entrants bringing incremental improvements in safety, tolerability, and convenience, similar to the MS market evolution.
• Pacing: Management expects Trontinemab data to mature in 2028; KRSA-028 aims to establish activity levels "at least as good as" Trontinemab based on early plaque clearance metrics.

Macro / Industry Outlook:

• Therapeutic Evolution: Views the current AD landscape (approved disease-modifying therapies) as merely the "first steps" in a larger evolution toward better therapeutic indices.
• Treatment Paradigm: Anticipates a shift away from inconvenient IV infusions requiring steroids and monitoring, moving toward at-home auto-injection to improve patient adherence and caregiver burden.
• Monitoring Burden: Acknowledges the high MRI monitoring burden associated with ARIA risk in current therapies; aims to generate data supporting reduced MRI frequency for lower-risk profiles in the future.

Strategic Initiatives:

• Formulation Innovation: Launching with a subcutaneous formulation designed from scratch (not a modification of an existing molecule) to achieve low viscosity and high concentration for low-volume monthly dosing.
• Mechanism Optimization: Employing "selective effector function modulation" (half-life extension, preserved phagocytosis, eliminated CDC/ADCC) to mitigate reticulocyte depletion and infusion reactions observed with competitors.
• Clinical Trial Design: Executing a unique three-part trial structure: (1) SAD in healthy volunteers (Aus/NZ), (2) MAD in patients (US), and (3) Expansion cohorts to define safety for Phase 3 entry.
• Population Strategy: Recruiting "all comers" including APOE4 homozygous patients to enable direct comparison against Trontinemab, rather than restricting trials to lower-risk cohorts.

Risks and Headwinds to Outlook:

• Safety Risks: Potential for Amyloid-Related Imaging Abnormalities (ARIA), microhemorrhage, and microedema, though management projects a "single-digit percentage" risk similar to Trontinemab.
• Clinical Uncertainty: Unknown if half-life extension will translate to faster plaque clearance than Trontinemab; current expectation is only that it allows for lower dosing frequency.
• Competitive Precedent: Reference to AbbVie/Alixata's AK-001 (no effector function) highlights the risk that novel mechanisms without phagocytosis may fail to show activity in clinic.
• Execution Risk: Reliance on successful data from a complex, integrated Phase 1/2 design to bypass traditional Phase 2; regulators may require more extensive safety characterization than anticipated.
• Commercial Barriers: High MRI monitoring requirements currently create payer and patient burden; success depends on proving a safety profile low enough to reduce this burden.

Management Tone on the Future:

• Confidence Level: High confidence in the technical feasibility of the subcutaneous formulation and the specific FC engineering to spare reticulocytes, citing strong preclinical differentiation in non-human primates.
• Strategic Focus: Emphasizes "laser-focused" execution on KRSA-028 rather than platform diversification, driven by the belief that this specific combination of features offers the best shot at a best-in-class molecule.
• Market Sentiment: Optimistic about the "evolution" of the field, viewing the current approved drugs as entry points that will necessitate superior safety/convenience to gain widespread market share.
• Transparency: Willing to socialize the story broadly to new investors; acknowledges the need to "move our program forward as fast as we can."

Miscellaneous:

• Capitalization: Company raised approximately $500 million and entered public markets a few months ago.
• Licensing: Lead asset (KRSA-028) licensed from Paragon Therapeutics.
• Analogy: Management draws a direct parallel between the current AD therapeutic landscape and the MS market "a generation ago," suggesting a similar trajectory of incremental innovation and multiple product winners.